Chronic cardiac allograft rejection: Critical role of ED-A + fibronectin and implications for targeted therapy strategies

Journal of Pathology

Volumn 226, Issue 4, 2012, Pages 557-561

  Franz, Marcus ^a   Neri, Dario ^b   Berndt, Alexander ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b ETH ZURICH   (Switzerland)

Author keywords

cardiac allograft vasculopathy; chronic cardiac allograft rejection; ED A + fibronectin; fibrosis; targeted therapy

Indexed keywords

ED A FIBRONECTIN; FIBRONECTIN; UNCLASSIFIED DRUG;

CARDIAC ALLOGRAFT VASCULOPATHY; CELL TYPE; CHRONIC GRAFT REJECTION; EXTRACELLULAR MATRIX; HEART MUSCLE FIBROSIS; HEART TRANSPLANTATION; HUMAN; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVIEW; VASCULAR SMOOTH MUSCLE;

ANIMALS; FEMALE; FIBRONECTINS; FIBROSIS; GRAFT REJECTION; HEART TRANSPLANTATION; MYOCARDIUM;

EID: 84856762879     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.3968     Document Type: Review

References (51)

1. Taylor DO, Edwards LB, Boucek MM, et al., Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report-2006. J Heart Lung Transplant 2006; 25: 869-879. (Pubitemid 44143013)
2. Jahania MS, Mullett TW, Sanchez JA, et al., Acute allograft failure in thoracic organ transplantation. J Card Surg 2000; 15: 122-128. (Pubitemid 32434297)
3. Ibrahim M, Hendry P, Masters R, et al., Management of acute severe perioperative failure of cardiac allografts: a single-centre experience with a review of the literature. Can J Cardiol 2007; 23: 363-367. (Pubitemid 46901895)
4. Hosenpud JD, Bennett LE, Keck BM, et al., The Registry of the International Society for Heart and Lung Transplantation: eighteenth Official Report-2001. J Heart Lung Transplant 2001; 20: 805-815. (Pubitemid 32737517)
5. Hosenpud JD, Bennett LE, Keck BM, et al., The Registry of the International Society for Heart and Lung Transplantation: fourteenth official report-1997. J Heart Lung Transplant 1997; 16: 691-712. (Pubitemid 27319146)
6. Armstrong AT, Binkley PF, Baker PB, et al., Quantitative investigation of cardiomyocyte hypertrophy and myocardial fibrosis over 6 years after cardiac transplantation. J Am Coll Cardiol 1998; 32: 704-710. (Pubitemid 28435257)
7. Taylor DO, Stehlik J, Edwards LB, et al., Registry of the International Society for Heart and Lung Transplantation: twenty-sixth official adult heart transplant report-2009. J Heart Lung Transplant 2009; 28: 1007-1022.
8. Vega JD, Moore J, Murray S, et al., Heart transplantation in the United States, 1998-2007. Am J Transplant 2009; 9: 932-941.
9. Suzuki J, Isobe M, Morishita R, et al., Characteristics of chronic rejection in heart transplantation: important elements of pathogenesis and future treatments. Circ J 2010; 74: 233-239.
10. Suzuki J, Isobe M, Aikawa M, et al., Nonmuscle and smooth muscle myosin heavy chain expression in rejected cardiac allografts. A study in rat and monkey models. Circulation 1996; 94: 1118-1124. (Pubitemid 26292869)
11. Mitchell RN,. Graft vascular disease: immune response meets the vessel wall. Annu Rev Pathol 2009; 4: 19-47.
12. Serini G, Gabbiani G,. Mechanisms of myofibroblast activity and phenotypic modulation. Exp Cell Res 1998; 250: 273-283.
13. Rohr S,. Myofibroblasts in diseased hearts: new players in cardiac arrhythmias? Heart Rhythm 2009; 6: 848-856.
14. Leask A,. Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res 2010; 106: 1675-1680.
15. Coito AJ, Binder J, de Sousa M, et al., The expression of extracellular matrix proteins during accelerated rejection of cardiac allografts in sensitized rats. Transplantation 1994; 57: 599-605. (Pubitemid 24075809)
16. Schupp DJ, Huck BP, Sykora J, et al., Right ventricular expression of extracellular matrix proteins, matrix-metalloproteinases, and their inhibitors over a period of 3 years after heart transplantation. Virchows Arch 2006; 448: 184-194. (Pubitemid 43237884)
17. Nozyjski J, Zakliczyjski M, Zembala-Nozyjska E, et al., Remodeling of human transplanted myocardium in ten-year follow-up: a clinical pathology study. Transplant Proc 2007; 39: 2833-2840.
18. Bowers SL, Banerjee I, Baudino TA,. The extracellular matrix: at the center of it all. J Mol Cell Cardiol 2010; 48: 474-482.
19. Schwarzbauer JE,. Fibronectin: from gene to protein. Curr Opin Cell Biol 1991; 3: 786-791. (Pubitemid 121006134)
20. Jones PL, Jones FS,. Tenascin-C in development and disease: gene regulation and cell function. Matrix Biol 2000; 19: 581-596.
21. Okamoto H, Imanaka-Yoshida K,. Matricellular proteins: new molecular targets to prevent heart failure. Cardiovasc Ther 2011; DOI: 10.1111/j.1755-5922.2011.00276.x.
22. Golledge J, Clancy P, Maguire J, et al., The role of tenascin C in cardiovascular disease. Cardiovasc Res 2011; 92: 19-28.
23. Gabler U, Berndt A, Kosmehl H, et al., Matrix remodelling in dilated cardiomyopathy entails the occurrence of oncofetal fibronectin molecular variants. Heart 1996; 75: 358-362. (Pubitemid 26155567)
24. Willems IE, Arends JW, Daemen MJ,. Tenascin and fibronectin expression in healing human myocardial scars. J Pathol 1996; 179: 321-325. (Pubitemid 26266413)
25. Astrof S, Hynes RO,. Fibronectins in vascular morphogenesis. Angiogenesis 2009; 12: 165-175.
26. Franz M, Brehm BR, Richter P, et al., Changes in extra cellular matrix remodelling and re-expression of fibronectin and tenascin-C splicing variants in human myocardial tissue of the right atrial auricle: implications for a targeted therapy of cardiovascular diseases using human SIP format antibodies. J Mol Histol 2010; 41: 39-50.
27. Franz M, Grün K, Richter P, et al., Extra cellular matrix remodelling after heterotopic rat heart transplantation: gene expression profiling and involvement of ED-A+ fibronectin, alpha-smooth muscle actin and B+ tenascin-C in chronic cardiac allograft rejection. Histochem Cell Biol 2010; 134: 503-517.
28. Franz M, Berndt A, Grün K, et al., Expression of extra domain A containing fibronectin in chronic cardiac allograft rejection. J Heart Lung Transplant 2011; 30: 86-94.
29. Coito AJ, Binder J, Brown LF, et al., TNF-alpha upregulates the expression of fibronectin in acutely rejecting rat cardiac allografts. Transplant Proc 1995; 27: 463-465.
30. Coito AJ, Brown LF, Peters JH, et al., Expression of fibronectin splicing variants in organ transplantation: a differential pattern between rat cardiac allografts and isografts. Am J Pathol 1997; 150: 1757-1772. (Pubitemid 27193822)
31. Coito AJ, de Sousa M, Kupiec-Weglinski JW,. Fibronectin in immune responses in organ transplant recipients. Dev Immunol 2000; 7: 239-248.
32. Coito AJ, Kato H, Azimi R, et al., Chronic allograft rejection versus tolerance: a critical role for EIIIA(+) fibronectin. Transplant Proc 2001; 33: 526-527. (Pubitemid 32237496)
33. Owens GK, Thompson MM,. Developmental changes in isoactin expression in rat aortic smooth muscle cells in vivo. Relationship between growth and cytodifferentiation. J Biol Chem 1986; 261: 13373-13380. (Pubitemid 17006921)
34. Dilley RJ, McGeachie JK, Prendergast FJ,. A review of the proliferative behaviour, morphology and phenotypes of vascular smooth muscle. Atherosclerosis 1987; 63: 99-107. (Pubitemid 17232739)
35. Desmoulière A, Gabbiani G,. The role of the myofibroblast in wound healing and fibrocontractive diseases. In The Molecular and Cellular Biology of Wound Repair, Clark RAF, (ed). Plenum Press: New York, 1996; 391-423.
36. Glukhova MA, Frid MG, Shekhonin BV, et al., Expression of extra domain A fibronectin sequence in vascular smooth muscle cells is phenotype dependent. J Cell Biol 1989; 109: 357-366. (Pubitemid 19180142)
37. Berndt A, Kosmehl H, Katenkamp D, et al., Appearance of the myofibroblastic phenotype in Dupuytren's disease is associated with a fibronectin, laminin, collagen type IV and tenascin extracellular matrix. Pathobiology 1994; 62: 55-58. (Pubitemid 24215140)
38. Kosmehl H, Berndt A, Katenkamp D,. Molecular variants of fibronectin and laminin: structure, physiological occurrence and histopathological aspects. Virchows Arch 1996; 429: 311-322. (Pubitemid 26421391)
39. Serini G, Bochaton-Piallat ML, Ropraz P, et al., The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1. J Cell Biol 1998; 142: 873-881. (Pubitemid 28381502)
40. Wallner K, Li C, Shah PK, et al., Tenascin-C is expressed in macrophage-rich human coronary atherosclerotic plaque. Circulation 1999; 99: 1284-1289. (Pubitemid 29129911)
41. Schellings MW, Pinto YM, Heymans S,. Matricellular proteins in the heart: possible role during stress and remodeling. Cardiovasc Res 2004; 64: 24-31. (Pubitemid 39208920)
42. Sawada Y, Onoda K, Imanaka-Yoshida K, et al., Tenascin-C synthesized in both donor grafts and recipients accelerates artery graft stenosis. Cardiovasc Res 2007; 74: 366-376. (Pubitemid 46693714)
43. Franz M, Berndt A, Altendorf-Hofmann A, et al., Serum levels of large tenascin-C variants, matrix metalloproteinase-9, and tissue inhibitors of matrix metalloproteinases in concentric versus eccentric left ventricular hypertrophy. Eur J Heart Fail 2009; 11: 1057-1106.
44. Booth AJ, Wood SC, Cornett AM, et al., Recipient-derived EDA fibronectin promotes cardiac allograft fibrosis. J Pathol 2011; 226: 609-618.
45. Stewart S, Winters GL, Fishbein MC, et al., Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24: 1710-1720. (Pubitemid 41641841)
46. Rybak JN, Roesli C, Kaspar M, et al., The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases. Cancer Res 2007; 67: 10948-10957. (Pubitemid 350145924)
47. Villa A, Trachsel E, Kaspar M, et al., A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer 2008; 122: 2405-2413. (Pubitemid 351590471)
48. Trachsel E, Bootz F, Silacci M, et al., Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis. Arthritis Res Ther 2007; 9: R9.
49. Rybak JN, Trachsel E, Scheuermann J, et al., Ligand-based vascular targeting of disease. ChemMedChem 2007; 2: 22-40.
50. Sauer S, Erba PA, Petrini M, et al., Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 2009; 113: 2265-2274.
51. Johannsen M, Spitaleri G, Curigliano G, et al., The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer 2010; 46: 2926-2935.